Recent evidence suggests that regression of left ventricular hypertrophy (LVH) following the use of angiotensin II (AII) receptor antagonists is to some extent independent of blood pressure (BP) changes. [1] [2] [3] These studies [1] [2] [3] raise the question of whether changes in BP, when treating hypertension and utilizing agents that inhibit the renin-angiotensin system (RAS) are indeed an appropriate clinical index of modifications in target organ damage. Although alterations in BP appear to be a useful clinical index in patients of European ancestry, 4 whether this effect is noted in populations of African ancestry whose BP responses to blockers of the RAS are quite distinct from other groups, 5 is uncertain. Indeed, previous data from our group suggest that the use of angiotensin-converting enzyme inhibitors (ACEI) result in reductions in LV mass (LVM) in hypertensives of African ancestry in association with little change in BP. 6 We were therefore concerned that the effects of reductions in BP on regression of LVM index (LVMI) may be eradicated by the reduction in LVMI, which is associated with minimal change in BP in response to ACEI. The question of whether decreases in BP predict regression of LVH is of particular importance in hypertensive groups of African ancestry who have higher LVH 7 and in whom electrocardiograph criteria are poor indicators of LVH, 8 thus necessitating the use of other clinical indicators of regression of LVH. Hence, the aim of our study was to determine whether in hypertensive subjects of African ancestry, change in BP can predict changes in LVMI in response to combination therapy including RAS blockers.
To address this issue, in a single centre, prospective, open-label study, we assessed the relationship between changes in BP and alterations in LVM following the use of agents that target the RAS used together with a diuretic agent, in hypertensives of African ancestry with LVH. Both an AII receptor blocker and an ACEI were studied as a degree of synergy exists in this combination. 9 Mild-to-moderate hypertensive men and women aged 21-70 years, who had LVH defined as LVM normalized for body surface area (LVMIÀLVMI BSA ) 4120 g/m 2 in males and 4100 g/m 2 in females (measured using two-dimensional targeted echocardiography 10 ), were recruited. LV dimensions were determined online by a technologist. All patients gave written consent. Patients underwent a 2-week washout period followed by a 2-week placebo run-in phase at which time 24 h ambulatory BP (ABP) monitoring was performed using SpaceLabs model 90207 oscillometric devices, programmed as previously described. 11 Patients were excluded if their medication compliance during the placebo run-in phase was poor (o80% or 4120% of the expected tablet count). Patients received candesartan cilexetil 8 mg once daily and if after a month BP control was not achieved (daytime diastolic BP (DBP) 490 mmHg) the dose of candesartan cilexetil was increased to 16 mg for a further month. If BP control was not achieved at the end of the 2-month treatment period, hydrochlorothiazide (HCTZ) 12.5 mg once daily was added for another month. If BP was still uncontrolled, patients were given ramipril 2.5 mg daily for another month, and the dose increased to 5 mg daily if required.
Of 167 patients screened, 86 patients fulfilled inclusion and exclusion criteria. In all, 47 patients completed 5 months of treatment. Of the 86 patients, 21 were withdrawn because of inappropriate BP control (mean 24-h systolic BP (SBP) exceeded 200 mmHg, or mean daytime DBP exceeded 114 mmHg), seven defaulted, one died of a motor vehicle accident, one suffered a nonfatal stroke, two patients developed anaemia and four patients an ACEI-related cough. Three patients did not have optimal echocardiograms. The characteristics (including body mass index of 31.276.7 kg/m 2 ) of the 47 patients completing the study were similar to the group initially recruited. At the end of the study three patients were receiving 16 mg candesartan daily, 12 patients 16 mg candesartan and 12.5 mg HCTZ daily, 10 patients 16 mg candesartan, 12.5 mg HCTZ and 2.5 mg ramipril daily, and the remaining 22 patients the maximum doses of all three agents.
A continuous decline in 24 h ABP (mmHg) was noted with the major effect occurring between 2 and 3 months when the diuretic was added (baseline ¼ 153717/9576; 2 months ¼ 150718/9378; 3 months ¼ 139721/8779; 5 months ¼ 135720/ 83710: change in BP at 5 months ¼ À18716/ À1179, Po0.0001 using repeated measures analysis of covariance with gender as a covariate). Regression of LVH (LVMI BSA in g/m 2 at baseline ¼ 122720 and at 5 months was 111723, Po0.001) was achieved by a reduction in LV wall thickness (Po0.001) and not by a decrease in LVEDD. A decrease in ambulatory 24 h, daytime and night-time SBP, but not office BP was correlated with reductions in LVM adjusted for both body surface area and height 2.7 (see Figure 1 for Pearson's correlation coefficients for LVMI BSA ). Using stepwise multiple regression models (SAS, version 9.1) and adjusting for gender and baseline LVMI the decrease in 24 h, daytime and night time systolic ABP were independent predictors of reductions in both LVMI BSA (24 h ABP, r ¼ 0.64, Po0.0001; daytime ABP, r ¼ 0.63, Po0.0001 and night time ABP, r ¼ 0.62, Po0.0001) and LVM adjusted for height 2.7 (24 h ABP, r ¼ 0.60, P ¼ 0.0002; daytime ABP, r ¼ 0.61, P ¼ 0.0002 and night time ABP, r ¼ 0.58, P ¼ 0.0005).
Data from the present study provide clear evidence that in hypertensive patients of African ancestry with LVH changes in ambulatory SBP associated with co-administration of an AII receptor blocker, candesartan, together with HCTZ (12.5 mg) and the ACEI ramipril (in 47% of patients) predict changes in LVMI. Therefore, these results indicate that change in BP may be used as a clinical indicator of regression of LVH in hypertensive patients of African ancestry receiving substances that target the RAS together with alternative agents. In other words, targeting the RAS in this population group does not appear to eradicate BP-dependent effects on LVH regression. A limitation of the present study was that the sonographer was aware of the temporal sequence of the echocardiograms in each patient. However, the sonographer was unaware of the BP in each patient.
Significantly, this is the first study to show that in subjects of African ancestry BP changes following the use of antihypertensive agents predict regression of LVM in patients with LVH irrespective of whether previous therapy had been utilized. Prior studies conducted in this population group have demonstrated that change in BP predict decreases in LVM in newly diagnosed, but not in previously treated patients irrespective of whether LVH was present. What is known (1) Regression of left ventricular hypertrophy (LVH) with reninangiotensin system (RAS) blockers is somewhat independent of blood pressure (BP) changes. [1] [2] [3] (2) BP changes nevertheless appear to be a useful clinical index of regression of LVH with RAS blockers in European groups. 4 (3) Patients of African ancestry have poor BP responses to RAS blockers and yet these agents still regress LVH. 6 Whether this masks the impact of BP changes on LVH regression in this group is not known.
What this study adds (1) This is the first study that shows a positive correlation between changes in left ventricular mass index (LVMI) and systolic BP in response to treatment in patients of African origin with LVH at baseline. (2) Moreover this association was noted in patients receiving RAS blockers in combination with other agents.
